Protalix BioTherapeuticsPLX
AMEXBiotech
No cached AI snapshot yet for PLX.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
226 employees80.57M shares outstandinglisted 1996-01-02
Next earnings ~May 5, 2026
About Protalix BioTherapeutics
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Latest News
Showing market-wide stock news
Bitcoin retreats after crypto bill setback, Fed next
This BlackRock strategist opposes a Fed hike. Here are the funds she recommends.
Gold outlook hinges on Fed signals; metal could test $4,200: Kotak Sec
US Dollar: Higher yields and oil support – MUFG
Bond Investors Are on Edge. Here's Why Stock Investors Should Pay Attention.
Wall St futures edge higher in countdown to Fed decision
Related Stocksin Biotech
Ready to see the live AI view on PLX?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing PLX side-by-side with live signals.